FindTrial
Sign In

Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)

Allogeneic Transplantation of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02235844
Enrollment
1
Registered
2014-09-10
Start date
2014-09-30
Completion date
2017-09-30
Last updated
2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne's Muscular Dystrophy

Keywords

Mesenchymal, Stem Cells, Umbilical Cord, Duchenne's, Muscular Dystrophy

Brief summary

This research study is designed to evaluate the effects of human umbilical cord mesenchymal stem cells (UC-MSCs), on Duchenne's muscular dystrophy (DMD). The potential muscle regenerative and anti-inflammatory properties of UC MSCs position them as a possible treatment option for DMD. Both of these properties could lead to potential benefits for a DMD patient.

Interventions

BIOLOGICALUmbilical Cord Mesenchymal Stem Cells

Sponsors

Aidan Foundation
CollaboratorUNKNOWN
Neil H. Riordan PhD
CollaboratorUNKNOWN
Allergy and Asthma Consultants, Wichita, Kansas
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
28 Years to 31 Years
Healthy volunteers
No

Inclusion criteria

* Duchenne's Muscular Dystrophy

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Adverse Events3 months after final treatmentNo occurrence of adverse events

Secondary

MeasureTime frame
Change from baseline of Predicted Forced Vital Capacity %3 months after final treatment
Change from baseline of weight3 months after final treatment
Change of muscle diameter (circumferential measurements) from baseline3 months after final treatment
Change from baseline of Predicted Maximum Expiratory Pressure %3 months after final treatment
Change from baseline of Pulmonary Forced Vital Capacity3 months after final treatment
Maximum Change from baseline of Predicted Inspiratory Pressure %3 months after final treatment
Change from baseline of Pulmonary Maximum Expiratory Pressure3 months after final treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026